2 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Placebo - Cap: new trials by email Literature Review of Placebo - Cap trials Research Report on Placebo - Cap
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. Dabigatran, Placebo - Cap - Mild Cognitive Impairment, Mild Alzheimer's Disease | Phase 1 | Withdrawn | University of Rhode Island | 2019-05-01 | 2025-04-17 | |
| INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Mifepristone, Placebo - Cap - Alcohol Use Disorder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 65 | 2017-09-26 | 2025-05-30 |
| Pharmacological Modulation of Belief Salience Placebo - Cap, L-dopa, Haloperidol - Haloperidol, Placebo | Phase 1 | Completed | King's College London | 30 | 2017-06-01 | 2019-10-10 |
Alcoholism (1) · Cognitive Dysfunction (1)
Johns Hopkins University (1) · King's College London (1) · University of Rhode Island (1)
United Kingdom (1) · United States (1)
John Stoukides, MD (1) · Mary E McCaul, PhD (1) · Paula Grammas, PhD (1)
PMID 12505794, PMID 16929307, PMID 20057930
U01AA020890 (1)